129 related articles for article (PubMed ID: 17918159)
1. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.
Kanda H; Ishii K; Ogura Y; Imamura T; Kanai M; Arima K; Sugimura Y
Int J Cancer; 2008 Jan; 122(2):444-51. PubMed ID: 17918159
[TBL] [Abstract][Full Text] [Related]
2. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
[TBL] [Abstract][Full Text] [Related]
3. Oral naftopidil suppresses human renal-cell carcinoma by inducing G(1) cell-cycle arrest in tumor and vascular endothelial cells.
Iwamoto Y; Ishii K; Sasaki T; Kato M; Kanda H; Yamada Y; Arima K; Shiraishi T; Sugimura Y
Cancer Prev Res (Phila); 2013 Sep; 6(9):1000-6. PubMed ID: 23901046
[TBL] [Abstract][Full Text] [Related]
4. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Yamada D; Nishimatsu H; Kumano S; Hirano Y; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Kume H; Homma Y
Int J Urol; 2013 Dec; 20(12):1220-7. PubMed ID: 23600973
[TBL] [Abstract][Full Text] [Related]
5. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
[TBL] [Abstract][Full Text] [Related]
6. Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.
Huang J; He F; Huang M; Liu X; Xiong Y; Huang Y; Zhu L; Yang Y; Xu X; Yuan M
Eur J Med Chem; 2015; 96():83-91. PubMed ID: 25874333
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human prostate cancer cells proliferation by a selective alpha1-adrenoceptor antagonist labedipinedilol-A involves cell cycle arrest and apoptosis.
Liou SF; Lin HH; Liang JC; Chen IJ; Yeh JL
Toxicology; 2009 Feb; 256(1-2):13-24. PubMed ID: 19056458
[TBL] [Abstract][Full Text] [Related]
8. Methylseleninic acid inhibits microvascular endothelial G1 cell cycle progression and decreases tumor microvessel density.
Wang Z; Hu H; Li G; Lee HJ; Jiang C; Kim SH; Lü J
Int J Cancer; 2008 Jan; 122(1):15-24. PubMed ID: 17847021
[TBL] [Abstract][Full Text] [Related]
9. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells.
Yim D; Singh RP; Agarwal C; Lee S; Chi H; Agarwal R
Cancer Res; 2005 Feb; 65(3):1035-44. PubMed ID: 15705905
[TBL] [Abstract][Full Text] [Related]
10. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.
Kojima Y; Sasaki S; Shinoura H; Hayase M; Kubota Y; Hayashi Y; Tsujimoto G; Kohri K
Prostate; 2007 Sep; 67(12):1285-92. PubMed ID: 17626248
[TBL] [Abstract][Full Text] [Related]
11. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors.
Takei R; Ikegaki I; Shibata K; Tsujimoto G; Asano T
Jpn J Pharmacol; 1999 Apr; 79(4):447-54. PubMed ID: 10361884
[TBL] [Abstract][Full Text] [Related]
12. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
13. Naftopidil reduced the proliferation of lung fibroblasts and bleomycin-induced lung fibrosis in mice.
Urushiyama H; Terasaki Y; Nagasaka S; Kokuho N; Endo Y; Terasaki M; Kunugi S; Makita K; Isago H; Hosoki K; Souma K; Ishii T; Matsuzaki H; Hiraishi Y; Mikami Y; Noguchi S; Tamiya H; Mitani A; Yamauchi Y; Shimizu A; Nagase T
J Cell Mol Med; 2019 May; 23(5):3563-3571. PubMed ID: 30873733
[TBL] [Abstract][Full Text] [Related]
14. Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells.
Gotoh A; Nagaya H; Kanno T; Nishizaki T
Pharmacology; 2012; 90(5-6):242-6. PubMed ID: 23007551
[TBL] [Abstract][Full Text] [Related]
15. Piperine inhibits the proliferation of human prostate cancer cells via induction of cell cycle arrest and autophagy.
Ouyang DY; Zeng LH; Pan H; Xu LH; Wang Y; Liu KP; He XH
Food Chem Toxicol; 2013 Oct; 60():424-30. PubMed ID: 23939040
[TBL] [Abstract][Full Text] [Related]
16. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
Zi X; Grasso AW; Kung HJ; Agarwal R
Cancer Res; 1998 May; 58(9):1920-9. PubMed ID: 9581834
[TBL] [Abstract][Full Text] [Related]
17. Naftopidil inhibits 5-hydroxytryptamine-induced bladder contraction in rats.
Sakai T; Kasahara K; Tomita K; Ikegaki I; Kuriyama H
Eur J Pharmacol; 2013 Jan; 700(1-3):194-200. PubMed ID: 23274492
[TBL] [Abstract][Full Text] [Related]
18. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells.
Chinni SR; Li Y; Upadhyay S; Koppolu PK; Sarkar FH
Oncogene; 2001 May; 20(23):2927-36. PubMed ID: 11420705
[TBL] [Abstract][Full Text] [Related]
19. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
Wang P; Ma Q; Luo J; Liu B; Tan F; Zhang Z; Chen Z
Cancer Invest; 2009 May; 27(4):369-75. PubMed ID: 19266349
[TBL] [Abstract][Full Text] [Related]
20. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
